SWOG S1803 (Multiple Myeloma)

What is the Purpose of this Study?

We are doing this study to see if adding the experimental drug daratumumab/rHuPH20 to the standard treatment after stem cell transplants can help multiply myeloma patients live longer.

What is the Condition Being Studied?

Multiple myeloma patients who have received a stem cell transplant

Who Can Participate in the Study?

Adults with multiple myeloma who have had a stem cell transplant.

Age Group
Adults

What is Involved?

If you choose to join this study, you will:

  • Be randomly assigned (like flipping a coin) to 1 of 2 groups
    • One group will take the standard maintenance drug, lenalidomide, and the study drug daratumumab/rHuPH20
    • The other group will take lenalidomide alone

Study Details

Full Title
SWOG S1803: Phase III Study of Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Principal Investigator
Headshot of Taewoong Choi
Assistant Professor of Medicine
Protocol Number
IRB: PRO00104040
NCT: NCT04071457
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate